Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28804025 | 0.78 | BCAT2 (0.42) | BCAT2MAPK8MAPK10GAAHSD17B10 | |
| SCHEMBL31322640 | 0.77 | BCAT2 (0.52) | BCAT2MAPK8MAPK10GAAHSD17B10 | |
| SCHEMBL4668673 | 0.74 | ALDH1A1 (0.44) | MAPK8MAPK10GAAHSD17B10ALOX5 | |
| SCHEMBL17152657 | 0.73 | BCAT2 (0.45) | BCAT2MAPK8MAPK10GAAHSD17B10 | |
| SCHEMBL2279587 | 0.73 | BCAT2 (0.47) | BCAT2MAPK8MAPK10GAAHSD17B10 | |
| SCHEMBL21356996 | 0.70 | BCAT2 (0.44) | BCAT2MAPK8MAPK10HSD17B10PKM | |
| SCHEMBL4667152 | 0.70 | BCAT2 (0.42) | BCAT2GAAHSD17B10MEN1ALDH1A1 | |
| SCHEMBL3077087 | 0.69 | PKM (0.43) | BCAT2MAPK8MAPK10GAAHSD17B10 | |
| SCHEMBL16087215 | 0.68 | BCAT2 (0.42) | BCAT2MAPK8MAPK10GAAPKM | |
| SCHEMBL3814101 | 0.68 | CDK8 (0.43) | BCAT2MAPK8MAPK10PKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287493-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-Y-AMINOALCOHOLS | BAYER SCHERING PHARMA AG (DE) | 2008-11-20 | — | — | US | claimed |
| WO-2008131972-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-GAMMA-AMINOALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | claimed |
| EP-1985612-A1 | Arymethylen substituted N-Acyl-gamma-aminoalcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | claimed |
| US-20080287493-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-Y-AMINOALCOHOLS | BAYER SCHERING PHARMA AG (DE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008131972-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-GAMMA-AMINOALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1985612-A1 | Arymethylen substituted N-Acyl-gamma-aminoalcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287493-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-Y-AMINOALCOHOLS | FSHR, CYP19A1, GNRHR | BCAT2 174/4885MAPK8 3134/4885MAPK10 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.